Haleon (LSE:HLN) Draws Fresh Attention As Excedrin Campaign Puts Valuation Back In Focus

Haleon (LSE:HLN) is back in the spotlight after its Excedrin brand introduced My Little Headache, a nostalgia driven digital pet, alongside the launch of aspirin free, caffeine free Excedrin Rapid Relief.

Haleon’s recent marketing push around Excedrin lands at a time when momentum in the shares has improved in the short term, with a 7.26% 7 day share price return and a 6.29% 30 day share price return, even though the year to date share price return is down 4.13% and the 90 day share price return has slipped 1.53%. At the same time, the 1 year total shareholder return of 5.81% and 3 year total shareholder return of 12.50% point to steadier progress for long term holders.

Scan beyond Haleon’s headlines and see how other consumer health and defensive businesses are shaping up in our hand picked screener of 7 high quality undervalued stocks.

Haleon’s share price bounce leaves a clear gap between the current £3.55 level and both analyst targets and intrinsic estimates. Is that spread signalling opportunity, or is it a warning on where fair value really sits?

Most Popular Narrative: 15% Overvalued

On the most followed view, Haleon screens as overvalued, with a fair value of £3.09 set against the latest £3.55 close. That gap rests on a more cautious read of how growth and margins play out over time.

While oral health brands such as Sensodyne and Parodontax continue to post high single digit growth and gain share, the 4.7% organic decline in Respiratory Health in the first half of 2026, including a 6.5% fall in the second quarter, shows that weakness in this sizeable category could keep dragging on overall revenue growth and limit operating leverage.

See why 2 investors see Haleon as 15% overvalued.

Result: Fair Value of £3.09 (OVERVALUED)

Still, if Haleon keeps compounding oral health growth and turns emerging market investment into stronger profit contribution, the bearish 15% overvaluation case could face pressure.

Find out about the key risks to this Haleon narrative.

Another View: Haleon Through A Cash Flow Lens

The bearish narrative leans on analyst targets around £3.09, yet Simply Wall St’s DCF model tells a different story. On that cash flow view, Haleon at £3.55 is trading below an estimated £6.26 future cash flow value, which suggests a very different risk reward balance.

To understand how sensitive that cash flow result is to the growth and margin assumptions that underpin it, and how it compares with the more cautious analyst view, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Haleon for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 7 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages on Haleon so far? Use that tension as a prompt to move quickly: weigh the evidence yourself, then drill into the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Haleon?

Do not stop with Haleon. Broaden your watchlist now, because the strongest opportunities often show up where fewer people are looking.

• Target resilient payers by scanning for dependable income opportunities through the 1 dividend fortresses.
• Hunt for quality at a discount by checking companies that screen well on cash flows and pricing in the 7 high quality undervalued stocks.
• Stack the odds in your favour by filtering for financially sturdy businesses using the list of solid balance sheet and fundamentals (9 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com